A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

January 31, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

ubenimex

OTHER

placebo

Trial Locations (31)

10065

Weill Cornell Medicine, New York

15212

Allegheny General Hospital, Pittsburgh

15213

University of Pennsylvania Medical Center, Pittsburgh

19104

University of Pennsylvania, Philadelphia

21205

Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore

27599

The University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University Medical Center, Durham

32610

University of Florida, Gainesville

33331

Cleveland Clinic, Florida, Weston

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

40202

Kentuckiana Pulmonary Associates, Louisville

44195

Cleveland Clinic Respiratory Institute, Cleveland

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic College of Medicine, Rochester

63130

Washington University, St Louis

75390

UT Southwestern Medical Center, Dallas

77030

Houston Methodist Hospital, Houston

78229

University Texas Health Science Center, San Antonio

80045

University of Colorado Denver, Aurora

90211

California Heart Center Foundation, An Affiliate of Cedars-Sinai Heart Institute, Cedars-Sinai Medical Care Foundation, Beverly Hills

92103

UCSD Medical Center, La Jolla

94305

Stanford University Medical Center, Stanford

04106

Chest Medicine Associates, South Portland

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

02118

Boston University School of Medicine, Boston

02903

Alpert Medical School of Brown University Rhode Island Hospital, Providence

N6A 5W9

London Health Sciences Centre, London

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

M5G 2N2

Toronto General Hospital, Toronto

Sponsors
All Listed Sponsors
lead

Eiger BioPharmaceuticals

INDUSTRY

NCT02664558 - A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) | Biotech Hunter | Biotech Hunter